Work

Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI: Interim results of the non-interventional AIO study QoLiTrap

Year: 2018

Type: article

Abstract: Introduction: The anti-angiogenic fusion protein aflibercept targets VEGF-A, VEGF-B and PlGF. Aflibercept is approved in combination with FOLFIRI for treatment of mCRC that is resistant or has progressed after oxaliplatin-containing therapy.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy151.259

Authors: M. Zahn, F. Scholten, R. von Moos, J. Thaler, R. Hofheinz

Institutions: Kantonsspital Graubünden, University Medical Centre Mannheim

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080